Stock Financial Ratios

TNDM / Tandem Diabetes Care, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)13.18
Enterprise Value ($M)76.05
Book Value ($M)-5.93
Book Value / Share-0.19
Price / Book-0.47
NCAV ($M)80.92
NCAV / Share2.65
Price / NCAV0.26
Income Statement (mra) ($M)
Net Income-83.45
Balance Sheet (mrq) ($M)
Cash & Equivalents12.08
Cash / Share0.40
Quick Ratio2.25
Current Ratio2.93
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-1.11
Return on Assets (ROA)-0.74
Return on Equity (ROE)14.08
Identifiers and Descriptors
Central Index Key (CIK)1438133
Industry Groups
SIC 3841 - Surgical and Medical Instruments and Apparatus
Other Related CUSIPS
Share Statistics
Common Shares Outstanding (M)10.12
Scoring Models
Piotroski F Score3.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Kaplan-Zingales KZ-IndexN/A
Cash Conversion CycleN/A
Per Share Metrics
Cash And Equivalents Per Share0.40
Liabilities Other Non Current Per Share0.22
Retained Earnings Per Share-15.25
Inventory Finished Goods Per Share0.47
Property Plant And Equipment Per Share0.66
Intangibles Per Share0.00
Assets Per Share2.88
Goodwill Per Share0.00
Accumulated Depreciation And Depletion Per Share0.00
Equity Per Share-0.91
Inventory Per Share0.98
Minority Interest Per Share0.00
Current Portion Of Long Term Debt Per Share0.00
Property Plant And Equipment Gross Per Share0.00
Assets Current Per Share1.83
Long Term Debt Per Share0.00
Cash Per Share0.40
Assets Other Current Per Share0.00
Treasury Stock Per Share0.00
Accounts Payable Per Share0.00
Accounts Receivable Per Share0.35
Preferred Stock Value Outstanding Per Share0.00
Assets Non Current Per Share0.00
Inventory Raw Materials Per Share0.33
Additional Paid In Capital Per Share14.33
Assets Other Non Current Per Share0.01
Inventory Work In Progress Per Share0.00
Liabilities Current Per Share0.96
Liabilities And Stock Equity Per Share2.88
Property Plant And Equipment Net Per Share0.66
Debt Per Share0.00
Deferred Income Tax Liabilities Per Share0.00
Liabilities Per Share3.79

Related News Stories

Insider Buying: Tandem Diabetes Care, Inc. (TNDM) CEO Buys $999,950.00 in Stock

2017-10-20 thecerbatgem
Tandem Diabetes Care, Inc. (NASDAQ:TNDM) CEO Kim D. Blickenstaff acquired 285,700 shares of Tandem Diabetes Care stock in a transaction that occurred on Friday, October 13th. The shares were bought at an average price of $3.50 per share, with a total value of $999,950.00. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. (41-6)

BRIEF-Tandem Diabetes Care announces proposed public offering of common stock

2017-10-12 reuters
* Tandem Diabetes Care announces proposed underwritten public offering of common stock, Series A warrants and Series B warrants Source text for Eikon: Further company coverage: (24-8)

The Zacks Analyst Blog Highlights: IDEXX Laboratories, Steris, K2M Group Holdings, Tandem Diabetes Care and Intersect ENT

2017-10-11 zacks
Chicago, IL – October 11, 2017 – announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include IDEXX Laboratories, Inc. (Nasdaq:(IDXX - Free Report)  – Free Report), Steris Corp. (NYSE:(STE - Free Report)  – Free Report), K2M Group Holdings, Inc. (195-0)

4 Top Growth Picks as MedTech Battle Rages On

2017-10-10 zacks
After several failed efforts to repeal and replace Obamacare, Trump’s government came up with a Graham-Cassidy-Heller-Johnson (“GCHJ”) bill or the Graham-Cassidy bill. However, this bill also failed to materialize. This we believe is a boon to the space as the Congressional Budget Office's (CBO) latest 'warning report' projected health coverage loss for millions of Americans due to a $1 trillion reduction in federal spending on Medicaid through 2026. (66-1)

5 MedTech Stocks for Stellar Returns in Q3

2017-10-10 zacks
While the Wall Street is gearing up for the third-quarter releases, the Republicans have lost another battle pertaining to the repeal of Affordable Care Act (ACA), or Obamacare, with the recent Graham-Cassidy bill defeat. (76-0)

CUSIP: 875372104